Aduro Biotech, Inc. today announced the presentation of updated data from an ongoing Phase 1b clinical trial of its immunotherapy product candidate CRS-207 in combination with pemetrexed and cisplatin as front-line treatment for patients with unresectable malignant pleural mesothelioma . The results from the first of two cohorts were presented today in a poster presentation at the 2016 American Society of Clinical Oncology Meeting held in Chicago.
